Grifols to Evaluate New Immunoglobulin Therapy Against COVID-19 in Spain
Shots: Alexion to acquire Syntimmune for $1.2B in cash, including an upfront payment of $400M, with additional milestone payments of up to $800M. The transaction is expected to close in Q4’18 Alexion to get the SYNT001 through this acquisition, which a humanized monoclonal antibody, which inhibits the binding of FcRn with Immunoglobulin G (IgG) and […]Read More
